X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (26546) 26546
Book Chapter (86) 86
Dissertation (39) 39
Publication (26) 26
Conference Proceeding (24) 24
Magazine Article (23) 23
Web Resource (10) 10
Book / eBook (4) 4
Newspaper Article (4) 4
Trade Publication Article (3) 3
Newsletter (2) 2
Paper (2) 2
Reference (2) 2
Book Review (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab (22404) 22404
humans (17458) 17458
female (10291) 10291
oncology (9159) 9159
male (8765) 8765
middle aged (7404) 7404
aged (6977) 6977
ophthalmology (6447) 6447
chemotherapy (5556) 5556
cancer (4984) 4984
angiogenesis inhibitors - therapeutic use (4904) 4904
adult (4892) 4892
treatment outcome (4688) 4688
vascular endothelial growth factor (4331) 4331
endothelial growth-factor (4301) 4301
antibodies, monoclonal, humanized (4165) 4165
vascular endothelial growth factor a - antagonists & inhibitors (4071) 4071
angiogenesis (3824) 3824
antineoplastic combined chemotherapy protocols - therapeutic use (3648) 3648
ranibizumab (3253) 3253
aged, 80 and over (3152) 3152
therapy (3057) 3057
care and treatment (3041) 3041
angiogenesis inhibitors - administration & dosage (3010) 3010
retrospective studies (2791) 2791
animals (2689) 2689
intravitreal injections (2676) 2676
metastasis (2514) 2514
antibodies, monoclonal - therapeutic use (2463) 2463
survival (2436) 2436
macular degeneration (2412) 2412
colorectal cancer (2351) 2351
vegf (2152) 2152
antibodies, monoclonal - administration & dosage (2106) 2106
medicine & public health (2087) 2087
antibodies, monoclonal, humanized - administration & dosage (2056) 2056
antibodies, monoclonal, humanized - therapeutic use (2024) 2024
research (1999) 1999
surgery (1981) 1981
trial (1950) 1950
colorectal neoplasms - drug therapy (1915) 1915
follow-up studies (1912) 1912
antineoplastic agents - therapeutic use (1902) 1902
patients (1899) 1899
prognosis (1892) 1892
tumors (1834) 1834
pharmacology & pharmacy (1833) 1833
tomography, optical coherence (1784) 1784
disease-free survival (1770) 1770
analysis (1749) 1749
drug therapy (1745) 1745
angiogenesis inhibitors - adverse effects (1671) 1671
eye diseases (1671) 1671
angiogenesis inhibitors (1655) 1655
clinical trials (1626) 1626
expression (1606) 1606
fluorescein angiography (1570) 1570
intravitreal bevacizumab (1565) 1565
combination (1528) 1528
colorectal neoplasms - pathology (1521) 1521
bevacizumab - administration & dosage (1473) 1473
visual acuity (1444) 1444
fluorouracil (1428) 1428
prospective studies (1427) 1427
oxaliplatin (1421) 1421
bevacizumab - therapeutic use (1417) 1417
paclitaxel (1352) 1352
cetuximab (1350) 1350
genetic structures (1347) 1347
antineoplastic combined chemotherapy protocols - adverse effects (1345) 1345
1st-line treatment (1328) 1328
cancer therapies (1301) 1301
antineoplastic agents (1296) 1296
mice (1279) 1279
efficacy (1262) 1262
neovascularization (1261) 1261
health aspects (1256) 1256
irinotecan (1242) 1242
lung neoplasms - drug therapy (1242) 1242
visual acuity - physiology (1221) 1221
antimitotic agents (1218) 1218
avastin (1212) 1212
hematology, oncology and palliative medicine (1209) 1209
leucovorin (1206) 1206
injection (1204) 1204
glioblastoma (1179) 1179
phase-ii trial (1175) 1175
diabetic retinopathy (1173) 1173
neoplasm staging (1163) 1163
neoplasm metastasis (1145) 1145
antibodies, monoclonal - adverse effects (1120) 1120
abridged index medicus (1119) 1119
phase-ii (1105) 1105
sense organs (1073) 1073
vascular endothelial growth factor a - metabolism (1069) 1069
risk factors (1063) 1063
combined modality therapy (1061) 1061
breast cancer (1060) 1060
open-label (1057) 1057
studies (1042) 1042
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (24717) 24717
German (602) 602
French (579) 579
Japanese (449) 449
Spanish (206) 206
Chinese (170) 170
Korean (170) 170
Portuguese (102) 102
Russian (77) 77
Turkish (59) 59
Czech (51) 51
Polish (50) 50
Hungarian (37) 37
Italian (22) 22
Romanian (13) 13
Norwegian (10) 10
Dutch (9) 9
Slovenian (8) 8
Finnish (5) 5
Danish (4) 4
Slovak (4) 4
Swedish (4) 4
Croatian (2) 2
Hebrew (2) 2
Arabic (1) 1
Bosnian (1) 1
Icelandic (1) 1
Indonesian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 20, pp. 1954 - 1963
The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase... 
Medicine(all) | MEDICINE, GENERAL & INTERNAL | METHYLATION | PROGNOSTIC-FACTORS | PLUS IRINOTECAN | SINGLE-AGENT BEVACIZUMAB | RESPONSE ASSESSMENT | CLINICAL-TRIALS | PHASE-2 | QUALITY-OF-LIFE | RADIOTHERAPY | TEMOZOLOMIDE | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Lomustine - adverse effects | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents, Alkylating - administration & dosage | Brain Neoplasms - drug therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Brain Neoplasms - mortality | Antineoplastic Agents, Alkylating - adverse effects | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Glioblastoma - mortality | Lomustine - administration & dosage | Patient outcomes | Lomustine | Outcome and process assessment (Health Care) | Dosage and administration | Research | Drug therapy | Glioblastoma multiforme | Methods | Medical research | Nuclear magnetic resonance--NMR | Brain cancer | Methylguanine | Glioblastoma | Clinical trials | Oncology | Cognition | Cancer therapies | Survival | Quality of life | Bevacizumab | O6-methylguanine-DNA methyltransferase | Studies | Brain research | DNA methylation | DNA methyltransferase | Cancer
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti‐vascular endothelial growth factor... 
Endocrine & metabolic | Receptors, Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor A | Macular oedema | Laser Coagulation | Visual Acuity | Retinal disease | Angiogenesis Inhibitors | Recombinant Fusion Proteins | Bevacizumab | Randomized Controlled Trials as Topic | Diabetic eye disease | Aptamers, Nucleotide | Ranibizumab | Quality of Life | Macular Edema | Diabetes | Eyes & vision | Network Meta‐Analysis | Triamcinolone | Medicine General & Introductory Medical Sciences | Diabetic Retinopathy | Retinal disease (including age‐related macular degeneration) | CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 77, pp. 13 - 20
Journal Article
Journal Article
Journal of biomedical materials research. Part A, ISSN 1549-3296, 2015, Volume 103, Issue 10, pp. 3148 - 3156
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2017, Volume 317, Issue 20, pp. 2072 - 2087
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Oxaliplatin | Monoclonal antibodies | Tumors
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1405 - 1414
Journal Article
Journal Article
Cochrane library, ISSN 1465-1858, 2018, Volume 2018, Issue 1, p. CD009734
Background Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis in foetal life. Researchers have recently attempted to use anti‐VEGF... 
Vascular Endothelial Growth Factor A | Eye Disorders | Intravitreal Injections | Laser Therapy | Combined Modality Therapy | Retinal disease | Angiogenesis Inhibitors | Retinopathy of Prematurity | Retinal diseases | Bevacizumab | Randomized Controlled Trials as Topic | Retinal Detachment | Other retinal diseases | Aptamers, Nucleotide | Neonatal care | Ranibizumab | Child health | Eyes & vision | Other neonatal care | Medicine General & Introductory Medical Sciences | Cryotherapy | AVASTIN | EFFICACY | Humans | Infant | Laser Therapy [methods] | DIODE-LASER | Aptamers, Nucleotide [administration & dosage] | MEDICINE, GENERAL & INTERNAL | THERAPY | Angiogenesis Inhibitors [administration & dosage] | INFANTS | Bevacizumab [administration & dosage] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Retinopathy of Prematurity [drug therapy] | AGGRESSIVE POSTERIOR RETINOPATHY | LASER TREATMENT | Retinal Detachment [prevention & control] | Newborn | Cryotherapy [methods] | ZONE-I | INTRAVITREAL BEVACIZUMAB | RANIBIZUMAB | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Aptamers, Nucleotide - administration & dosage | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Aptamers, Nucleotide - adverse effects | Ranibizumab - adverse effects | Angiogenesis Inhibitors - administration & dosage | Retinopathy of Prematurity - drug therapy | Laser Therapy - methods | Ranibizumab - administration & dosage | Cryotherapy - methods | Retinal Detachment - prevention & control | Angiogenesis Inhibitors - adverse effects | Infant, Newborn
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2017, Volume 53, pp. 25 - 37
•Cranial SRT is well tolerated when combined with the majority of immuno- or targeted therapies.•Cranial SRT concurrent with BRAF-Inhibitors should be... 
Targeted therapy | Toxicity | Concurrent | Immunotherapy | Stereotactic radiotherapy | LOCALLY-RECURRENT | OLIGOPROGRESSIVE DISEASE |